For more than 40 years, beta blockers have been considered a cornerstone in the treatment of patients after a heart attack. Millions of people worldwide have received these medications as a standard part of their recovery plan, with the aim of reducing the risk of further heart complications.
However, a new international study casts significant doubt on this long-established practice, suggesting that beta blockers may be far less beneficial than previously believed—and that, for women, they could even increase health risks.
The research, known as the REBOOT study, was published in the respected medical journal "New England Journal of Medicine." The study included a large and diverse group of heart attack patients from multiple countries, providing robust data and broad applicability.
Researchers analyzed the outcomes of patients who received beta blockers compared to those who did not. Surprisingly, the results indicate that, for many patients, beta blockers did not offer any clear advantage in preventing further cardiac events or improving long-term survival.
Even more alarming was the finding that women may experience adverse effects from beta blockers after a heart attack. The study observed that female patients taking these medications were at a higher risk of complications compared to those who did not receive them. The reasons for this gender-specific difference remain under investigation, but the evidence is strong enough to prompt a re-evaluation of current treatment guidelines.
The implications of these findings are significant. For decades, beta blockers have been prescribed almost automatically to heart attack survivors, based on earlier studies that suggested clear benefits. This new research challenges that assumption and highlights the need for more personalized approaches to treatment. It also underscores the importance of including women in clinical trials and analyzing data by gender, as responses to medications can differ between men and women.
Medical professionals are now faced with the task of re-examining their prescribing habits. The REBOOT study’s results could lead to changes in official guidelines and influence how doctors treat heart attack patients worldwide. For patients, especially women, this research brings hope for safer and more effective therapies in the future.
In summary, while beta blockers have long been viewed as essential after a heart attack, new scientific evidence suggests their benefits are often overrated, and their risks—especially for women—cannot be ignored. This pivotal study may usher in a new era of more targeted and individualized heart attack care. Published August 30, 2025 DOI: 10.1056/NEJMoa2504735 Ibanez et Al, Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid